2179.Hk
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
Business. The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
The company's capital structure is characterized by a debt-to-equity ratio of 0.9, indicating a relatively balanced mix of debt and equity financing. Its liquidity position is assessed as medium, with a current ratio of 1.0, suggesting that the company has just enough current assets to cover its current liabilities. The price-to-book ratio of 4.43 implies that the market values the company at a premium to its book value, which may reflect expectations of future growth or intangible assets.
Profitability metrics reveal a challenging financial position, with a return on equity of -0.8648 and a return on assets of -0.3465, both indicating a loss-making operation. The company reported a net loss of 610,390,000 CNY, with an operating loss of 584,274,000 CNY, which is significantly below the industry median for profitability metrics. These figures suggest that the company is not currently generating sufficient operating income to cover its costs and is likely relying on external financing or asset sales to sustain operations.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks associated with market-specific downturns or regulatory changes in its primary operating region.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The high enterprise value to revenue ratio of 268.51 suggests that the market is valuing the company's revenue at a very high multiple, which may be based on speculative growth expectations rather than current earnings performance. This valuation could be at risk if the company fails to meet these expectations.
Risk factors include a medium liquidity risk, as the company's net cash is negative after subtracting total debt, indicating potential challenges in meeting short-term obligations. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. However, the company's negative net income and operating income suggest that it may need to raise additional capital in the future, which could lead to dilution of existing shareholders' equity.
Recent events, as disclosed in the latest financial filings, include a significant operating and net loss, which may signal financial distress or a strategic shift in the company's operations. No specific events such as new product launches, regulatory approvals, or major partnerships are mentioned in the available data, which limits the ability to assess the company's strategic direction or market position.
- The company is currently operating at a loss, with a return on equity of -0.8648 and a return on assets of -0.3465.
- The company's liquidity position is medium, with a current ratio of 1.0, indicating a balanced but potentially fragile liquidity position.
- The company's valuation is based on high multiples, with an enterprise value to revenue ratio of 268.51, which may be speculative.
- The company's revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing its exposure to market-specific risks.
- The company's debt-to-equity ratio of 0.9 suggests a balanced capital structure, but the negative net cash position after subtracting total debt indicates potential liquidity challenges.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 2179.HK Market data — financials · 2026-05-26